Edward K Mulholland
Overview
Explore the profile of Edward K Mulholland including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
192
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Toh Z, Russell F, Garland S, Mulholland E, Patton G, Licciardi P
JNCI Cancer Spectr
. 2021 Mar;
5(2):pkab011.
PMID: 33748668
The current global novel coronavirus disease 2019 (COVID-19) pandemic threatens to derail the uptake of human papillomavirus (HPV) vaccination in low- and lower-middle income countries with major disruptions to routine...
2.
Rajapaksa A, Do L, Ong D, Sourial M, Veysey D, Beare R, et al.
Front Pharmacol
. 2020 Sep;
11:1291.
PMID: 32973520
Objective: Current prevention and/or treatment options for respiratory syncytial virus (RSV) infections are limited as no vaccine is available. Prophylaxis with palivizumab is very expensive and requires multiple intramuscular injections...
3.
Toh Z, Kosasih J, Russell F, Garland S, Mulholland E, Licciardi P
Infect Drug Resist
. 2019 Jul;
12:1951-1967.
PMID: 31308715
Human papillomavirus (HPV) types 16 and 18 cause 70% of cervical cancer cases globally. The nonavalent HPV vaccine (9vHPV) was licensed in 2014 and protects against the next five most...
4.
Toh Z, Cheow K, Russell F, Hoe E, Reyburn R, Fong J, et al.
Open Forum Infect Dis
. 2018 Jul;
5(7):ofy147.
PMID: 30019002
Background: This study examined the cellular immunity of 0, 1, 2, and 3 doses of Gardasil vaccine (4vHPV) in girls after 6 years and their responses to a subsequent dose...
5.
OGrady K, Chang A, Cripps A, Mulholland E, Smith-Vaughan H, Wood N, et al.
Hum Vaccin Immunother
. 2018 Jun;
14(11):2768-2779.
PMID: 29944440
We aimed to determine the efficacy of the 10-valent pneumococcal- protein D conjugate vaccine (PHiD-CV) in children aged 18-months to <18-years with recurrent protracted bacterial bronchitis (rPBB), chronic suppurative lung...
6.
Toh Z, Licciardi P, Russell F, Garland S, Batmunkh T, Mulholland E
Asian Pac J Cancer Prev
. 2017 Sep;
18(9):2339-2343.
PMID: 28950675
Cervical cancer is ranked the first or second most common cancer in women of low- and middle-income countries
(LMICs) in Asia. Cervical cancer is almost exclusively caused by human papillomavirus...
7.
Toh Z, Russell F, Reyburn R, Fong J, Tuivaga E, Ratu T, et al.
Clin Infect Dis
. 2016 Dec;
64(7):852-859.
PMID: 28034886
Background: The duration of antibody response following reduced human papillomavirus (HPV) vaccine doses has not been determined. We compared the antibody responses in girls previously vaccinated with zero, 1, 2,...
8.
Licciardi P, Toh Z, Clutterbuck E, Balloch A, Marimla R, Tikkanen L, et al.
J Allergy Clin Immunol
. 2016 Jan;
137(6):1772-1779.e11.
PMID: 26825000
Background: A randomized controlled trial in Fiji examined the immunogenicity and effect on nasopharyngeal carriage after 0, 1, 2, or 3 doses of 7-valent pneumococcal conjugate vaccine (PCV7; Prevnar) in...
9.
Toh Z, Licciardi P, Fong J, Garland S, Tabrizi S, Russell F, et al.
Vaccine
. 2015 Aug;
33(39):5042-50.
PMID: 26271829
Human papillomavirus (HPV) infection is the primary cause of genital warts, some oropharyngeal cancers and anogenital cancers, including cervical, vagina, vulvar, anal and penile cancers. Primary prevention of cervical cancer...
10.
Licciardi P, Russell F, Balloch A, Burton R, Nahm M, Gilbert G, et al.
Vaccine
. 2014 Mar;
32(20):2321-7.
PMID: 24613524
The impact of prior nasopharyngeal carriage on serotype-specific IgG responses following immunization with pneumococcal conjugate vaccines (PCV) has recently been described. This report extends these findings to describe the attenuation...